Key result
Pegylated interferon alfa-2a and ribavirin linked to bronchiolitis obliterans organizing pneumonia after 36 weeks.
Why the study?
Pulmonary toxicity associated with interferon during treatment of chronic hepatitis C is rarely described.
Case Report (n=1)
Pegylated interferon alfa-2a and ribavirin treatment for chronic hepatitis C can rarely cause severe pulmonary toxicity such as bronchiolitis obliterans organizing pneumonia.
May warrant vigilance for organizing pneumonia during pegylated interferon therapy; leaves open incidence and causality.
The treatment of chronic hepatitis C has frequent side effects such as cytopenias and neuropsychiatric symptoms. However, pulmonary toxicity associated with interferon is rarely described. This paper describes the clinical case of a 67-year-old female patient with chronic hepatitis C who presented an acute onset of dry cough, dyspnoea, and fever 36 weeks after the use of pegylated interferon alfa-2a and ribavirin. The lung biopsy confirmed the diagnosis of a bronchiolitis obliterans organizing pneumonia (BOOP). Corticotherapy was initiated, with clinical and radiological improvement. This paper aims to advise physicians to this occasional, though severe, adverse event related to hepatitis C virus (HCV) treatment.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2012) conducted a case report in Chronic hepatitis C (n=1). Pegylated interferon alfa-2a and ribavirin was evaluated. Treatment with pegylated interferon alfa-2a and ribavirin in a patient with chronic hepatitis C was associated with the development of bronchiolitis obliterans organizing pneumonia after 36 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: